Mayne Pharma: Building for the future

Mayne Pharma invested $80m investment in its Greenville, NC-based oral-dose commercial manufacturing facility that has been repurposed with 10 additional manufacturing suites as well as an expanded pre-commercial lab footprint

It also features a new visitor and staff administration footprint and stability center of excellence, which is part of an additional $3.5m investment

“We expect our licenses and permits to come in the third quarter of 2017 with production beginning in January 2018,​” said Kimberly McClintock, Executive VP, Metrics Contract Services. “Now we can stay with our partners all the way through commercial manufacturing​.”

McClintock added that it’s aiming to “circumvent some of the challenges of tech transfer​.”

Specifically, Mayne pharma is expanding capabilities in solvent handling, potent products, controlled substances, and modified release drug delivery.

 “We’re building for the future​,” said McClintock. “We’re on track to hit our goals​.”